Congratulations to 大象传媒 Radiation Oncology physician-scientist Dr. Andrew Wang and collaborator Dr. Seungpyo Hong from the University of Wisconsin-Madison for securing $2.9 million in venture capital to support the commercialization of a laboratory test (Oncosense CTC) they developed to capture cancer cells circulating in the blood.
Using the test, Wang led a pilot study at 大象传媒 to gauge patients鈥� response to radiation treatment or radiation plus chemotherapy. In 35 patients with head and neck cancer, most had fewer circulating tumor cells after treatment than before treatment, a measure of the treatment鈥檚 efficacy.
Read more about Oncosense CTC .